TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tempest Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.60−0.02 (-3.86%)
Close on Oct 19, 2026
- Market cap
- $9.14M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.9%
1M of 15M shares
Institutional holders
20
4 new, 5 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $1.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Matthew Angel | 5,531,516 | 37.40% | 13D (active) amendment | Mar 24, 2026 |
| Sabby Management, LLC | 492,223 | 9.90% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TPST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sabby Management, LLC | 511,286 | 3.45% | $567.53K | +493,430 | 0.51% |
| Vanguard Capital Management LLC | 233,888 | 1.58% | $259.62K | – | 0.00% |
| Geode Capital Management, LLC | 86,625 | 0.59% | $96.16K | −365 | 0.00% |
| Vanguard Fiduciary Trust Co | 68,908 | 0.47% | $76.49K | – | 0.00% |
| BlackRock, Inc. | 39,068 | 0.26% | $43.37K | – | 0.00% |
| Squarepoint Ops LLC | 30,900 | 0.21% | $34.30K | New | 0.00% |
| Northern Trust Corp | 20,136 | 0.14% | $22.35K | +6,083 | 0.00% |
| Citadel Advisors LLC | 19,820 | 0.13% | $22.00K | New | 0.00% |
| UBS Group AG | 5,636 | 0.04% | $6.26K | +1,103 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,922 | 0.03% | $4.35K | +1,132 | 0.00% |
| Morgan Stanley | 2,022 | 0.01% | $2.24K | −36 | 0.00% |
| Osaic Holdings, Inc. | 1,513 | 0.01% | $1.67K | −16 | 0.00% |
| Federation des caisses Desjardins du Quebec | 292 | 0.00% | $324 | – | 0.00% |
| Jones Financial Companies Lllp | 239 | 0.00% | $258 | – | 0.00% |
| Barclays PLC | 222 | 0.00% | $246 | New | 0.00% |
| SBI Securities Co., Ltd. | 56 | 0.00% | $62 | – | 0.00% |
| Royal Bank of Canada | 28 | 0.00% | $0 | +1 | 0.00% |
| Parallel Advisors, LLC | 18 | 0.00% | $20 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 3 | 0.00% | $3 | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 3 | 0.00% | $3 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 20 | 1M | 6.9% | 4 / 5 | 3 / 5 | 1M | 0M |
| Q1 2026 | 21 | 1M | 3.5% | 5 / 3 | 3 / 2 | 0M | 0M |
| Q4 2025 | 20 | 1M | 3.5% | 6 / 3 | 4 / 2 | 0M | 0M |
| Q3 2025 | 16 | 0M | 2.1% | 3 / 7 | 1 / 4 | 0M | 0M |
| Q2 2025 | 17 | 1M | 4.6% | 16 / 0 | 1 / 1 | 1M | 4M |
| Q1 2025 | 2 | 4M | 23.7% | 2 / 0 | 0 / 0 | 4M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TPST | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 128,944 | 0.87% | $143.13K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 104,944 | 0.71% | $116.49K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 50,985 | 0.34% | $78.01K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 15,677 | 0.11% | $23.99K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 7,495 | 0.05% | $11.47K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Angel | CEO and President, Director, 10% owner | 5,068,552 | 34.23% | Jun 23, 2026 |
| Stephen R. Brady | President and CEO, Director | 46,376 | 0.31% | Jan 6, 2025 |
| Nicholas Maestas | Chief Financial Officer | – | – | Apr 2, 2026 |
| Justin Trojanowski | Corporate Controller | 22,168 | 0.15% | Apr 2, 2026 |
| Samuel Whiting | Chief Medical Officer | 9,573 | 0.06% | Jan 6, 2025 |
| John D. Yee | Director | – | – | Jun 17, 2026 |
| William Drake Richey | Director | 2,000 | 0.01% | Jun 8, 2026 |
| Ronit Simantov | Director | – | – | Jan 28, 2026 |
| Geoffrey Nichol | Director | – | – | Jan 28, 2026 |
| Christine A. Pellizzari | Director | – | – | Jan 28, 2026 |
| Michael Raab | Director | – | – | Jan 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew Angel CEO and President, Director, 10% owner | Mar 24, 2026 | Buy | +231,482 | $2.16 | $500.00K | 231,482 |
| Matthew Angel CEO and President, Director, 10% owner | Mar 24, 2026 | Buy | +231,482 | $2.16 | $500.00K | 231,482 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 12, 2024 | Sale | −387,999 | $1.10 | $426.80K | 209,941 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 8, 2024 | Sale | −400,000 | $1.35 | $540.00K | 597,940 |
| Stephen R. Brady President and CEO, Director | Jul 3, 2024 | Buy | +35,000 | $2.11 | $73.85K | 46,376 |
| Samuel Whiting Chief Medical Officer | Jul 2, 2024 | Buy | +4,672 | $2.13 | $9.95K | 9,573 |
| Justin Trojanowski Corporate Controller | Jun 28, 2024 | Buy | +7,500 | $2.16 | $16.20K | 22,168 |
| Thomas Woiwode Director, 10% owner | Apr 29, 2022 | Buy | +2,118,644 | $2.36 | $5.00M | 2,118,644 |
| Thomas W. Dubensky President, Director | Jan 7, 2022 | Buy | +2,000 | $4.78 | $9.56K | 113,343 |
| Samuel Whiting Chief Medical Officer | Jan 6, 2022 | Buy | +1,700 | $4.80 | $8.16K | 1,901 |
| Samuel Whiting Chief Medical Officer | Jun 25, 2021 | Award | +201 | – | – | 201 |
| Thomas W. Dubensky President, Director | Jun 25, 2021 | Award | +111,343 | – | – | 111,343 |
| Thomas Woiwode Director, 10% owner | Jun 25, 2021 | Award | +997,940 | – | – | 997,940 |
| Thomas Woiwode Director, 10% owner | Jun 25, 2021 | Award | +1,171,094 | – | – | 1,171,094 |
| Thomas Woiwode Director, 10% owner | Jun 25, 2021 | Award | +7,377 | – | – | 7,377 |
| Pierre Lorenzo Corporate Controller | Jun 25, 2021 | Award | +53 | – | – | 53 |
| Stella Xu Director | Jun 25, 2021 | Award | +579,710 | – | – | 579,710 |
| Carol Giltner Gallagher Director | Dec 7, 2018 | Award | +23,684 | – | – | 23,684 |
| Carol Giltner Gallagher Director | Dec 7, 2018 | Award | +8,249 | – | – | 8,249 |
| Pharis Mohideen Chief Medical Officer | Dec 7, 2018 | Award | +7,440 | – | – | 7,440 |
| Mary Fisher Director | Dec 7, 2018 | Award | +355 | – | – | 3,319 |
| Richard Aldrich Director | Dec 7, 2018 | Award | +755 | – | – | 6,169 |
| Randall W. Whitcomb Director | Dec 7, 2018 | Award | +15,784 | – | – | 15,784 |
| Marc D. Kozin Director | Dec 7, 2018 | Award | +831 | – | – | 7,740 |
| Julia C. Owens President and CEO, Director | Dec 7, 2018 | Award | +74,400 | – | – | 74,400 |
| Marc D. Kozin Director | Sep 28, 2018 | Award | +16,014 | – | – | 103,647 |
| Mary Fisher Director | Sep 28, 2018 | Award | +6,851 | – | – | 44,460 |
| Richard Aldrich Director | Sep 28, 2018 | Award | +14,558 | – | – | 81,220 |
| Richard Aldrich Director | Jun 29, 2018 | Award | +11,709 | – | – | 66,662 |
| Marc D. Kozin Director | Jun 29, 2018 | Award | +12,880 | – | – | 87,633 |
| Mary Fisher Director | Jun 29, 2018 | Award | +5,510 | – | – | 37,609 |
| Marc D. Kozin Director | Mar 30, 2018 | Award | +14,411 | – | – | 74,753 |
| Mary Fisher Director | Mar 30, 2018 | Award | +6,165 | – | – | 32,099 |
| Richard Aldrich Director | Mar 30, 2018 | Award | +13,101 | – | – | 54,953 |
| Mary Fisher Director | Dec 29, 2017 | Award | +3,571 | – | – | 25,934 |
| Marc D. Kozin Director | Dec 29, 2017 | Award | +8,348 | – | – | 60,342 |
| Richard Aldrich Director | Dec 29, 2017 | Award | +7,589 | – | – | 41,852 |
| Mary Fisher Director | Sep 29, 2017 | Award | +3,521 | – | – | 22,363 |
| Marc D. Kozin Director | Sep 29, 2017 | Award | +8,230 | – | – | 51,994 |
| Richard Aldrich Director | Sep 29, 2017 | Award | +7,482 | – | – | 34,263 |
| Richard Aldrich Director | Jun 30, 2017 | Award | +6,810 | – | – | 26,781 |
| Marc D. Kozin Director | Jun 30, 2017 | Award | +6,477 | – | – | 43,764 |
| Mary Fisher Director | Jun 30, 2017 | Award | +3,205 | – | – | 18,842 |
| Thomas Malley Director | Jun 13, 2017 | Award | +7,873 | – | – | 204,981 |
| Thomas Malley Director | Mar 31, 2017 | Award | +7,085 | – | – | 197,108 |
| Mary Fisher Director | Mar 31, 2017 | Award | +2,673 | – | – | 15,637 |
| Marc D. Kozin Director | Mar 31, 2017 | Award | +5,180 | – | – | 37,287 |
| Richard Aldrich Director | Mar 31, 2017 | Award | +5,681 | – | – | 19,971 |
| Richard Aldrich Director | Dec 30, 2016 | Award | +6,944 | $1.53 | $10.62K | 14,290 |
| Thomas Malley Director | Dec 30, 2016 | Award | +8,660 | $1.53 | $13.25K | 190,023 |
| Marc D. Kozin Director | Dec 30, 2016 | Award | +6,331 | $1.53 | $9.69K | 32,107 |
| Mary Fisher Director | Dec 30, 2016 | Award | +3,267 | $1.53 | $5.00K | 12,964 |
| Christophe Couturier Chief Financial Officer | Dec 23, 2016 | Award | +300 | $1.44 | $432 | 50,900 |
| Richard Aldrich Director | Dec 22, 2016 | Gift | −154,519 | – | – | 7,346 |
| Richard Aldrich Director | Dec 22, 2016 | Gift | +154,519 | – | – | 330,000 |
| Richard Aldrich Director | Dec 13, 2016 | Gift | −645,842 | – | – | 161,865 |
| Richard Aldrich Director | Dec 13, 2016 | Gift | +645,842 | – | – | 668,192 |
| Richard Aldrich Director | Dec 7, 2016 | Gift | −200,000 | – | – | 0 |
| Richard Aldrich Director | Dec 7, 2016 | Gift | +200,000 | – | – | 807,707 |
| Thomas Malley Director | Sep 30, 2016 | Award | +1,850 | – | – | 181,363 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. Owner | Aug 13, 2024 | 387,999 | $426.99K | Aug 12, 2024 | private offering |
| Versant Venture Capital VI, L.P. 10% Stockholder | Aug 9, 2024 | 400,000 | $7.21M | Aug 8, 2024 | private offering |
| Thomas W. Dubensky Officer, Director | Nov 2, 2023 | 30,000 | $131.45K | Oct 25, 2023 | early exercise |